|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
These findings further characterize a mechanism by which gefitinib treatment of NSCLC harboring EGFR(L858R) leads to a dramatic response to gefitinib.
|
15492241 |
2004 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here, we show that L858R and deletion mutant EGFR proteins found in NSCLC interact with the chaperone and are sensitive to degradation following Hsp90 inhibition.
|
16024644 |
2005 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Patients with NSCLC and EGFR exon 19 deletions have a longer survival following treatment with gefitinib or erlotinib compared with those with the L858R mutation.
|
16818686 |
2006 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The mutations consisted of the recurrent missense L858R and in-frame deletion delE746-A750, previously characterized as activating EGFR mutations in non-small cell lung cancer.
|
16857803 |
2006 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Mutations of the epidermal growth factor receptor (EGFR), particularly deletional mutations (DEL) in exon 19 and L858R in exon 21, are reportedly correlated with clinical outcome in patients with non-small cell lung cancer (NSCLC) receiving the EGFR tyrosine kinase inhibitors gefitinib and erlotinib, suggesting that detection of EGFR mutations would have an important role in clinical decision making.
|
16938658 |
2006 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Exogenous expression of either the L858R point mutant or the DeltaE746-E750 deletion mutant form of EGFR in immortalized human bronchial epithelial cells, p53 WT NSCLC (A549), or p53-null NSCLC (NCI-H1299) resulted in dramatically increased sensitivity to IR.
|
17018617 |
2006 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
HRMA is a precise method for detecting DEL and L858R mutations and is useful for predicting clinical outcomes in patients with advanced NSCLC treated with gefitinib.
|
17875767 |
2007 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Although most EGFR mutations detected are short deletions in exon 19 or the L858R point mutation in exon 21, more than 75 different EGFR kinase domain residues have been reported to be altered in NSCLC patients.
|
17877814 |
2007 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this study, we attempted to evaluate the effect of cetuximab on several NSCLC lines harboring some of the more common EGFR mutations (L858R and delL747-T753insS), as well as the recently identified kinase inhibitor-resistant mutation, T790M.
|
17913857 |
2007 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Three NSCLC cell lines with varying EGFR mutation status and sensitivities to EGFR-TKIs were selected: H3255 (L858R), H1650 (del E746-A750), and H1781 (wild-type EGFR).
|
17948911 |
2007 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Exon19 deletions and exon21 L858R mutations in EGFR were detected in 4 (12%) and 13 (38%) of 34 NSCLC cases, respectively.
|
18448998 |
2008 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this study, we showed that HRMA is a highly accurate method for detecting DEL and L858R mutations in patients with NSCLC, although it is necessary to consider the identification of patients with a false-negative result when the analysis is conducted using small samples.
|
18676744 |
2008 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The gefitinib response rate of NSCLC with exon 20 mutations was 25%, far lower than those with deletions in exon 19 and L858R mutations.
|
18676761 |
2008 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Seven of these mutations were novel, and one was the L858R mutation described in non-small-cell lung cancer.
|
18998063 |
2009 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The most common NSCLC-associated EGFR mutations are deletions in exon 19 and L858R mutation in exon 21, together accounting for 90% of EGFR mutations.
|
19366827 |
2009 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Most advanced non-small-cell lung cancers (NSCLCs) with activating epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to the EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib.
|
19632948 |
2009 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In 77 TTNAs (71.3.%) that were positive for non-small cell lung cancer, the variant in exon 21 (the missense mutation at codon 858, L858R) and the deletion in exon 19 (in frame deletion at codons 747-749) of the EGFR gene, and the point mutation in exon 2 of KRAS were investigated with HRM assay using sequencing as the reference "gold standard".
|
19640859 |
2009 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We examined the diagnostic accuracy of the cumulative smoking dose for identifying the epidermal growth factor receptor (EGFR) exon 19 deletion and L858R mutation among Japanese patients with non-small-cell lung cancer (NSCLC).
|
19650855 |
2009 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Exon 19 deletion mutations and the single-point substitution mutation L858R in exon 21 are the most frequent in NSCLC and are termed 'classical' mutations.
|
19680293 |
2009 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We retrospectively analyzed a cohort of 100 patients with stage IIIB/IV NSCLC screened for two major EGFR mutations (exon 19 deletions and L858R mutation).
|
19777258 |
2010 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We were able to identify EGFR mutations in NSCLC tumor samples immunohistochemically with a sensitivity of 79% using the anti-delE746-A750 antibody and 83% using the anti-L858R antibody.
|
20423982 |
2010 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Further on, we performed a retrospective evaluation of seven patients with advanced EGFR-mutated (exon 19 deletions and L858R) NSCLC that were given erlotinib at 25 mg/d as their first EGFR TKI.
|
20512075 |
2010 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Advanced non-small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations (deletion in exon 19 or L858R) show an impressive progression-free survival of 14 months when treated with erlotinib.
|
21233402 |
2011 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We used this method in a survey of 73 non-small cell lung cancer (NSCLC) samples, detecting 14 mutant samples of E746_A750del and 12 mutant samples of L858R.
|
21439672 |
2011 |
|
rs121434568
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We were able to identify EGFR mutations in NSCLC effusion and CSF with a sensitivity of 100% (5/5) using the anti-delE746-A750 antibody and 100% (8/8) using the anti-L858R antibody.
|
21444121 |
2011 |